Status:
COMPLETED
An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Methamphetamine Addiction
Crystal Meth Addiction
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
More people worldwide use amphetamine-type stimulants than any illicit drug besides cannabis, and methamphetamine (MA) abuse and dependence is the fastest growing drug problem in the United States. Mu...
Detailed Description
Study Procedures: Study participants are those who meet criteria for MA dependence, who are not seeking treatment, and who also meet criteria for nicotine dependence. Participants will be asked to we...
Eligibility Criteria
Inclusion
- Be English-speaking volunteers who are not seeking treatment at the time of the study;
- Be between 18-55 years of age;
- Meet DSM-IV TR criteria for MA dependence;
- Must be cigarette smokers, defined as smoking 10 or more cigarettes per day by self-report;
- Have a self-reported history of using MA by the smoked or IV route and provide at least one MA-positive urine prior to admission;
- Have vital signs as follows: resting pulse between 50 and 90 bpm, blood pressures between 105-150 mm Hg systolic and 45-90 mm Hg diastolic; this criterion must be met within 2 days of admission;
- Have hematology and chemistry laboratory tests that are within normal (+/- 10%) limits with the following exceptions: a) liver function tests (total bilirubin, ALT, AST, and alkaline phosphatase) \< 3 x the upper limit of normal, and b) kidney function tests (creatinine and BUN) \< 2 x the upper limit of normal;
- Have a baseline EKG that demonstrates normal sinus rhythm, normal conduction (including QTc), and no clinically significant arrhythmias;
- Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the admitting physician or nurse practitioner and the principal investigator.
Exclusion
- Have any history or evidence suggestive of seizure disorder or brain injury
- Have any previous medically adverse reaction to MA, including loss of consciousness, chest pain, or epileptic seizure
- Have neurological or psychiatric disorders, such as
- psychosis, bipolar illness or major depression as assessed by SCID;
- organic brain disease or dementia assessed by clinical interview;
- history of any psychiatric disorder which would require ongoing treatment or which would make study compliance difficult;
- history of suicide attempts within the past three months assessed by SCID and/or current suicidal ideation/plan as assessed by SCID;
- Have evidence of clinically significant heart disease or hypertension, as determined by the PI;
- Have a family history in first-degree relatives of early cardiovascular morbidity or mortality, as determined by the PI;
- Have evidence of untreated or unstable medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease;
- Have HIV and are currently symptomatic, have a diagnosis of AIDS, or are receiving antiretroviral medication;
- Be pregnant or nursing. Other females must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or be using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide). All females must provide negative pregnancy urine tests before study entry, upon hospital admission, and at the end of study participation;
- Have asthma or currently use alpha or beta agonists, theophylline, or other sympathomimetics;
- Have any other illness, condition, or use of psychotropic medications, which in the opinion of the PI and/or the admitting physician or nurse practitioner would preclude safe and/or successful completion of the study.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00713479
Start Date
July 1 2008
End Date
September 1 2009
Last Update
March 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA NPI
Los Angeles, California, United States, 90095